Get the Stockscreener App
20.80
0.19%
-0.04
After Hours:
20.80
Newamsterdam Pharma Company Nv stock is traded at $20.80, with a volume of 139.13K.
It is down -0.19% in the last 24 hours and up +8.96% over the past month.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
See More
Previous Close:
$20.84
Open:
$21
24h Volume:
139.13K
Relative Volume:
0.36
Market Cap:
$1.93B
Revenue:
$14.09M
Net Income/Loss:
$-176.94M
P/E Ratio:
-7.8043
EPS:
-2.6652
Net Cash Flow:
$-141.24M
1W Performance:
+3.95%
1M Performance:
+8.96%
6M Performance:
+10.52%
1Y Performance:
+110.95%
1-Day Range:
$20.64
$21.05
1-Week Range:
$19.78
$21.66
52-Week Range:
$8.90
$26.35
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Name
Newamsterdam Pharma Company Nv
Sector
Industry
Phone
35 206 2971
Address
GOOIMEER 2-35, NARRDEN
Compare NAMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
20.80 | 1.93B | 14.09M | -176.94M | -141.24M | -2.6652 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-24 | Initiated | TD Cowen | Buy |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-18-24 | Initiated | Guggenheim | Buy |
| Jan-16-24 | Initiated | Piper Sandler | Overweight |
| Oct-30-23 | Initiated | RBC Capital Mkts | Outperform |
Newamsterdam Pharma Company Nv Stock (NAMS) Latest News
NewAmsterdam Pharma (NASDAQ:NAMS) Earns “Buy” Rating from Needham & Company LLC - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by Jennison Associates LLC - MarketBeat
Needham & Company LLC Reiterates Buy Rating for NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma Reports Promising Phase 3 Trial Results - Yahoo Finance
NewAmsterdam Pharma target raised to $45 on strong trial data By Investing.com - Investing.com Nigeria
NewAmsterdam Pharma target raised to $45 on strong trial data - Investing.com
Newamsterdam’s obicetrapib combo nails phase III LDL-C endpoints - BioWorld Online
NewAmsterdam Pharma stock falls on trial data (NAMS:NASDAQ) - Seeking Alpha
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH - The Manila Times
NewAmsterdam Pharma stock holds Overweight rating with catalysts ahead in Ph3 topline readouts - Investing.com
Trend Tracker for (NAMSW) - Stock Traders Daily
Frazier Life Sciences Bolsters Leadership with Two Senior Industry Veterans | NAMS Stock News - StockTitan
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 - The Manila Times
NewAmsterdam's Obicetrapib Achieves 41.5% LDL-C Reduction in Phase 3 Trial | NAMS Stock News - StockTitan
RA Capital Management, L.P. Expands Stake in NewAmsterdam Pharma Co NV - GuruFocus.com
GSA Capital Partners LLP Has $1.10 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) surges 13%; private equity firms who own 46% shares profited along with institutions - Simply Wall St
When the Price of (NAMS) Talks, People Listen - Stock Traders Daily
Is NewAmsterdam Pharma (NAMS) Top Performing European Stock Heading into 2025? - Insider Monkey
10 Top Performing European Stocks Heading into 2025 - Insider Monkey
Lisanti Capital Growth LLC Invests $700,000 in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Q4 EPS Forecast for NewAmsterdam Pharma Reduced by Analyst - Defense World
William Blair Issues Pessimistic Forecast for NAMS Earnings - MarketBeat
Leerink Partnrs Has Bullish Outlook for NAMS FY2024 Earnings - MarketBeat
Equities Analysts Offer Predictions for NAMS FY2024 Earnings - Defense World
Leerink Partnrs Has Strong Estimate for NAMS FY2028 Earnings - Defense World
Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $33.80 - Defense World
(NAMSW) Proactive Strategies - Stock Traders Daily
What is Leerink Partnrs' Forecast for NAMS FY2028 Earnings? - MarketBeat
NewAmsterdam Pharma Reports Strong Q3 and Trial Progress - TipRanks
NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma - Benzinga
Newamsterdam Pharma Faces Compliance Cost Surge as Emerging Growth Status Ends - TipRanks
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $33.80 Consensus PT from Analysts - MarketBeat
NewAmsterdam Pharma Revenue Soars 900%, Reports Strong Q3 Results Ahead of Key Trial Data | NAMS Stock News - StockTitan
abrdn plc Purchases 53,060 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
(NAMS) Technical Pivots with Risk Controls - Stock Traders Daily
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November - The Manila Times
[Complimentary] New Amsterdam repositions obicetrapib selectively for advanced cardiovascular disease patients | $NAMS - substack.com
Needham Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN
NewAmsterdam Pharma to Restate Prior Financials - Investing.com India
NewAmsterdam Pharma to Restate Prior Financials By Investing.com - Investing.com Australia
(NAMSW) Trading Report - Stock Traders Daily
NewAmsterdam Pharma Breaks Above 200-Day Moving AverageBullish for NAMS - Nasdaq
Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) Target Price at $33.80 - MarketBeat
NewAmsterdam Pharma Company N.V. (NAMS) Price Target Increased by 8.93% to 31.11 - MSN
Marshall Wace LLP Decreases Stake in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
When the Price of (NAMSW) Talks, People Listen - Stock Traders Daily
Millennium Management LLC Has $22.39 Million Stock Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Newamsterdam Pharma Company Nv Stock (NAMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):